Science Advisory Board

To position itself at the forefront of the biomanufacturing landscape, Vitrian formed a Science Advisory Board comprised of subject matter experts across advanced therapeutics development and contract manufacturing, clinical operations, CQV, private equity, and venture capital. The Science Advisory Board complements Vitrian’s in-house expertise with a breadth of perspectives and decades of experience.

  • Jim Graham, CFA, MBA,
    Research Bridge Partners

    • Managing Director of Investments for TX- based life science VC firm focused on bringing coastal funders to support university- adjacent early-stage biotech companies outside of the coastal gateway clusters
    • Former bio company executive with experience in standing up and exiting commercial manufacturing operations
    • Extensive experience/relationships in TX life science community
  • Jeff Gilmore, PE, PMP

    • President and Managing Partner of market- leading project management, process development and technical support consultant for cGMP biomanufacturing
    • Previously co-founded Vista Engineering Group,provider of owner’s rep and engineering services for bio companies
    • Over 30 years’ experience standing up pilot scale to full commercialization manufacturing facilities
    • Extensive experience/relationships in Southern CA and CO life science communities
  • Brian Radecki
    Rapa Therapeutics

    • Founder and CEO of MD-based clinical-stage cell therapy company focused on cancer, neurodegenerative and autoimmune diseases spun out of National Cancer Institute in 2017.
    • Former CFO, CoStar Group
    • Active angel investor and board member of ACV Auctions, Wheels Up Partners Holdings, and Rosecliff Acquisitions Corp.
  • Deborah Wild

    • Advisory Board Member of GeneVentiv Therapeutics
    • Over 30 years’ biopharma executive experience with focus on advanced therapeutics at Cellipont Bioservices, Paragon/Catalent, and Genentech.
    • President and CEO of Southern CA and TX-based cell and gene therapy CDMO, former Chief Quality and Regulatory Affairs Officer and Chief of Staff at Paragon Bioservices
    • US Army Veteran and board member of several non-profits focused on veterans support
    • Extensive experience/relationships in Southern CA and MD life science communities
  • Tyler Brous
    Lennox Capital Partners, TX-based biotech and real estate investment firm

    • Managing Director at Lennox Capital Partners
    • Serves on ColdQuanta’s board of directors
    • Previously worked at Arog Pharmaceuticals, an oncology focused pharmaceutical company, in various roles including CFO
  • Isaac Ro
    Catalio Capital Management / Haystack Oncology

    • Over 20 years of experience in the life sciences sector with a particular focus on genomics, oncology and bioproduction
    • Partner at Catalio Capital Management, LP
    • Executive Chairman of Haystack Oncology. Previously, he served as CFO of Sema4 (went public in 2021) and CFO of Thrive Earlier Detection (acquired by Exact Sciences for $2.1 billion)
    • Before that, 16 years on Wall Street as an award-winning equity research analyst at Goldman Sachs and SVB Securities
  • Scott Rizzo
    COO and Senior VP
    Societal CDMO

    • Over 30 years’ of leadership and operational experience primarily in oral solid dose (OSD) manufacturing.
    • Held positions at Roche Pharmaceuticals, Barrier Therapeutics, J. Knipper, Dupont, and PWC
    • Board Member of Georgia Bio and leads employee development and community relations endeavors with Greater Hall Chamber of Commerce
  • Yun Jeong Song, MD
    Matica Biotechnology

    • President of Matica Holdings
    • Over 20 years of research, patient care, and immuno-oncology therapy development background
    • Former CEO/CMO of ImmuneOncia and Clinical Director at Sanofi
    • Extensive experience/relationships in Korea and Korean-American life science communities


For inquiries or more information, contact us at 240.396.1414
or fill out the form below.

This field is for validation purposes and should be left unchanged.